Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

131 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
No increased prevalence of malignancies among first-degree relatives of 800 patients with chronic myeloid leukemia: a population-based study in Sweden.
Gunnarsson N, Höglund M, Stenke L, Sandin F, Björkholm M, Dreimane A, Lambe M, Markevärn B, Olsson-Strömberg U, Wadenvik H, Richter J, Själander A. Gunnarsson N, et al. Among authors: wadenvik h. Leukemia. 2017 Aug;31(8):1825-1827. doi: 10.1038/leu.2017.131. Epub 2017 May 2. Leukemia. 2017. PMID: 28461694 Free article. No abstract available.
Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registry.
Flygt H, Sandin F, Dahlén T, Dremaine A, Lübking A, Markevärn B, Myhr-Eriksson K, Olsson K, Olsson-Strömberg U, Själander A, Söderlund S, Wennström L, Wadenvik H, Stenke L, Höglund M, Richter J. Flygt H, et al. Among authors: wadenvik h. Br J Haematol. 2021 Jun;193(5):915-921. doi: 10.1111/bjh.17392. Epub 2021 Mar 30. Br J Haematol. 2021. PMID: 33782950 Free article.
Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow-up of patients diagnosed 2002-2017 in a complete coverage and nationwide agnostic register study.
Dahlén T, Edgren G, Ljungman P, Flygt H, Richter J, Olsson-Strömberg U, Wadenvik H, Dreimane A, Myhr-Eriksson K, Zhao J, Själander A, Höglund M, Stenke L. Dahlén T, et al. Among authors: wadenvik h. Am J Hematol. 2022 Apr;97(4):421-430. doi: 10.1002/ajh.26463. Epub 2022 Jan 20. Am J Hematol. 2022. PMID: 35015312 Free PMC article.
Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry.
Höglund M, Sandin F, Hellström K, Björeman M, Björkholm M, Brune M, Dreimane A, Ekblom M, Lehmann S, Ljungman P, Malm C, Markevärn B, Myhr-Eriksson K, Ohm L, Olsson-Strömberg U, Själander A, Wadenvik H, Simonsson B, Stenke L, Richter J. Höglund M, et al. Among authors: wadenvik h. Blood. 2013 Aug 15;122(7):1284-92. doi: 10.1182/blood-2013-04-495598. Epub 2013 Jul 10. Blood. 2013. PMID: 23843494 Free PMC article.
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.
Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM; ENESTnd Investigators. Saglio G, et al. N Engl J Med. 2010 Jun 17;362(24):2251-9. doi: 10.1056/NEJMoa0912614. Epub 2010 Jun 5. N Engl J Med. 2010. PMID: 20525993 Free article. Clinical Trial.
IL1RAP antibodies block IL-1-induced expansion of candidate CML stem cells and mediate cell killing in xenograft models.
Ågerstam H, Hansen N, von Palffy S, Sandén C, Reckzeh K, Karlsson C, Lilljebjörn H, Landberg N, Askmyr M, Högberg C, Rissler M, Porkka K, Wadenvik H, Mustjoki S, Richter J, Järås M, Fioretos T. Ågerstam H, et al. Among authors: wadenvik h. Blood. 2016 Dec 8;128(23):2683-2693. doi: 10.1182/blood-2015-11-679985. Epub 2016 Sep 12. Blood. 2016. PMID: 27621309 Free article.
131 results